AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer

British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.

from Reuters: Health News https://ift.tt/2Ot69Fs
via IFTTT